



13 October 2010

IMUGENE SIGNS GLOBAL AGREEMENT

- *Licensing discussions to commercialise Imugene's pig and poultry vaccines successfully completed*
- *Exclusive license to Imugene's technologies granted to major international animal health company*

Imugene Limited (ASX: IMU) announced today that it has signed a global agreement with one of the world's leading animal health companies to commercialise its vaccines for pigs and poultry.

The agreement signed with Novartis Animal Health, a business unit within the global Novartis Group, gives the company exclusive global rights to all of Imugene's technologies and intellectual properties, including its vaccines and productivity enhancers.

Specific terms of the agreement are not being disclosed. Novartis will pay the costs of developing products, and Imugene will receive an initial payment as well as milestone payments and royalties on product sales.

Dr Warwick Lamb, CEO of Imugene said "We are pleased to have executed an agreement with Novartis, a top international animal health company. "This is a very good outcome for Imugene and its shareholders and lays the foundation for a fruitful, long term partnership. We are looking forward to working with Novartis to progress our technology through evaluation and product development to sales."

Imugene is developing a range of biologically based vaccines for pigs and poultry, which are safer and easier to use than chemical based products. They have the potential to improve the health and welfare of these animals and address some of the major diseases and health issues threatening pig and poultry production worldwide,

Imugene's business model is to maximise income from the receipt of research fees, license and royalty income from an alliance partner with sufficient expertise and infrastructure to develop, market and exploit the Imugene range of vector vaccines.

ABN 99 009 179 551

Registered Office

Level 20, Allendale Square, 77 St Georges Terrace, Perth WA 6000

Tel +61 8 94402660 Fax +61 8 9 4402699

www.imugene.com

About Imugene

Imugene Limited (ASX Code: IMU) specialises in the development and commercialisation of novel animal health products for pigs and poultry. Our range of products under development includes vaccines to prevent important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock.

For more information please visit the Imugene Website www.imugene.com or contact:

Dr Warwick Lamb
Managing Director

+61 2 9870 7330

Mr Graham Dowland
Executive Chairman

+61 8 9440 2660

Kyahn Williamson
Investor Relations
Buchan Consulting
+61 3 9866 4722 / +61
40101 8828